Table 2.
Clinical characteristics of patients in which use of intention to treat was reported in two groups
| Variables | Month |
mAD group
(n = 34) |
Control group
(n = 32) |
P * |
|---|---|---|---|---|
| Number of seizure attacks per months (mean ± SD) | First | 5.26 ± 2.81 | 6.34 ± 3.06 | 0.141 |
| Second | 3.61 ± 1.88 | 5.84 ± 2.92 | < 0.001 | |
| P** | 0.006 | 0.001 | ||
| 50% reduction in seizure frequency [n (%)] | First | 6 (17.60) | 0 (0) | 0.037 |
| Second | 12 (35.30) | 0 (0) | 0.001 | |
| P** | 0.084 | - | ||
| Seizure free [n (%)] | First | 0 (0) | 0 (0) | - |
| Second | 0 (0) | 0 (0) | - | |
| P** | - | - | ||
| BMI (kg/m2) (mean ± SD) | First | 23.07 ± 3.60 | 22.95 ± 1.80 | 0.860 |
| Second | 22.32 ± 3.52 | 23.02 ± 1.94 | 0.365 | |
| P** | 0.038 | 0.237 | ||
| Increasing cholesterol level during 2 months [n (%)] | 7 (20.59) | 0 (0) | 0.004 | |
| Increasing liver enzyme during 2 months [n (%)] | 5 (14.71) | 5 (15.62) | 0.007 | |
| The mean urinary ketone positivity during 2 months (mean ± SD) | 1.75 ± 0.28 | - | - | |
SD: Standard deviation; mAD: Modified Atkins diet
*
Significant level for comparing two groups in each months,
**
Significant level for comparing two month in each groups.